NCT00645814View on ClinicalTrials.gov

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

148

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

September 30, 2003

Conditions

Psoriasis

Interventions

DRUG

placebo for adalimumab

80 mg at Week 0 and 40 mg eow through Week 11

DRUG

adalimumab

80 mg at Week 0 and 40 mg eow through Week 11

DRUG

adalimumab

80 mg at Week 0 and 40 mg weekly through Week 11

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Abbott

INDUSTRY